Abstract: Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and/or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.

Abstract: Certain embodiments of the present invention provide systems and methods for retrieving and re-identifying patient data. Patient data may be re-identified by retrieving an encrypted or abstracted patient identifier. The identifier is used to retrieve a patient identifier associated with patient identification information. Patient identification information may be inserted into a file, such as a report or other document, at a local computer or web portal for access by an authorized user. A system includes a data storage storing patient data. The patient data includes an encoded patient identifier and an unencoded patient identifier. The system includes a workstation or other processor having a viewing application capable of viewing patient data in a file including the encoded patient identifier. The workstation invokes a procedure to replace the encoded patient identifier in the file at the workstation with the corresponding unencoded patient identifier using the data storage.

Abstract: Certain embodiments of the present invention provide a system and method for processing medical data. The method includes the steps of identifying text strings in medical data, associating the text strings with standardized identifiers from a library, and outputting the standardized identifiers associated with the text strings. In an embodiment, a report and/or an order including the standardized identifiers associated with the text strings may be printed and/or stored. In an embodiment, the library may be modified to accommodate the text strings. A user and/or software program may be used to review the text strings to associate the standardized identifiers with the text strings, for example. In an embodiment, the text strings may be deconstructed into a plurality of sub-strings. A standardized identifier is then associated with each sub-string. The standardized identifiers may be numeric values, for example.

Abstract: An immunogenic composition is described that preferably contains a recombinantly produced form of truncated West Nile envelope glycoprotein and one or more adjuvants acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent populations. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) West Nile protein. An adjuvant typically comprises a saponin, saponin-based adjuvant (e.g., ISCOMATRIX® or GPI-0100), emulsion-based adjuvant (e.g., Co-Vaccine HT), or alum-based adjuvant. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition.

Abstract: An immunogenic composition is described which preferably contains recombinantly produced forms of truncated flavivirus envelope glycoproteins and an adjuvant. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) flavivirus protein. The adjuvant typically comprises a saponin preferably derived from the Quillaja saponica tree or a derivative thereof. The adjuvant can also comprise an oligodeoxyribonucleotide preferably containing specific sequences of nucleotides described herein. A pharmaceutically acceptable vehicle may also be included in the immunogenic composition.

Abstract: Human monophenotypic cloned cell lines of megakaryocytic lineage are established in vitro through use of adherent stromal cells in long term human bone marrow culture. Long term bone marrow cultures are used for initial adaptation of the cells to culture conditions. Once adapted, cells of the human in vitro cell lines are weaned from the stromal layer until they proliferate in the complete absence of any feeder layer. Seed cells for establishment of human in vitro cell lines were derived from a human solid tumor designated as ATCC CRL 9139 xenograft. Cells of one cloned in vitro cell line designated as CHRF-288-11 exhibits a karyotype and markers characteristic of megakaryocytes and platelets. Cells of the CHRF-288-11 cell line express platelet peroxidate, platelet factor IV, platelet Ca.sup.++ -ATPase, gpIIbIIIa, factor VIII, and MY7, MY9 and HLA-Dr antigens. CHRF-288-11 cell line exhibits a constant karyotype (50, XY).

Abstract: Information-theoretic notions are employed to establish the predictability of a random number generated from a circuit exhibiting chaos in order to obtain a number from a sequence of numbers with a known level of randomness and security. The method provides a measure of information loss whereby one may select the number of iterations before or between bit sampling in order to extract a secure pseudo-random number. A chaotic output is obtained by use of a sample and hold circuit coupled in a feedback loop to a variable frequency oscillator, such as a voltage controlled oscillator circuit, and operated with a positive Lyapunov exponent. A source signal generator, such as a periodic wave generator, provides a driving signal to the sample and hold circuit.